Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Receivables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Receivables for 8 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 1923.4% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 1923.4% increase, with the full-year FY2024 number at $229000.0, down 74.58% from a year prior.
  • Receivables was $3.8 million for Q3 2025 at Precision Biosciences, up from $4000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $50.5 million in Q2 2022 to a low of $4000.0 in Q1 2025.
  • A 5-year average of $4.7 million and a median of $570000.0 in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 10249.8% in 2022, then crashed 98.97% in 2025.
  • Precision Biosciences' Receivables stood at $488000.0 in 2021, then skyrocketed by 47.54% to $720000.0 in 2022, then increased by 25.14% to $901000.0 in 2023, then plummeted by 74.58% to $229000.0 in 2024, then skyrocketed by 1561.14% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Receivables are $3.8 million (Q3 2025), $4000.0 (Q1 2025), and $229000.0 (Q4 2024).